MGet It

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

By Cardillo, Thomas M; Govindan, Serengulam V; Sharkey, Robert M; Trisal, Preeti; Arrojo, Roberto; Liu, Donglin; Rossi, Edmund A; Chang, Chien-Hsing; Goldenberg, David M

Publication Date: 2015

Journal: Bioconjugate chemistry.

Volume: 26

Issue: 5

Page: 919-931

ISSN: 1043-1802

Resource: Article

PMID: 25915780

DOI: 10.1021/acs.bioconjchem.5b00223

Go To Item(opens in new tab)

American Chemical Society Journals
Available from 01/01/1990 volume: 1 issue: 1.
Go To Item(opens in new tab)

American Chemical Society Journals
Ann Arbor campus | Access to the ACS online version restricted (authentication may be required):

Found a problem? Let our team of link fixers know.

MGet It

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Not available online?

Get Help